Acute lung injury (ALI) is a life-threatening syndrome characterized by dysregulated inflammatory responses, disruption of the alveolar–vascular barrier, and severe respiratory dysfunction. With a complex pathogenesis and high mortality, ALI remains a major clinical challenge. Traditional Chinese medicine (TCM) offers distinctive therapeutic advantages in ALI management through its integrated regulatory mechanism involving “multiple-components, multiple-targets, and multiple-pathways”. TCM monomers, TCM compound prescriptions, and Chinese proprietary medicines have been shown to attenuate pulmonary pathology by suppressing the release of pro-inflammatory mediator, inhibiting inflammatory signaling cascades, modulating immune cell polarization, and alleviating oxidative stress. Retrieve relevant literature from PubMed, Web of Science, and Google Scholar databases based on abstracts, conclusions, and experimental content. Based on the aforementioned literature, this review systematically examines the mechanistic basis by which TCM regulates inflammation in ALI, beginning with the pivotal role of inflammation in disease progression, and aims to provide insights to guide TCM pharmacological research and novel drug development in this field.
Xu et al. (Sun,) studied this question.